Related Experiment Video

Updated: May 9, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

[DEDD decreases Smad3 activity, promotes tumor cell apoptosis and inhibits proliferation]

Fang Hua1, Jian-Fei Xue, Xiao-Xi Lü

  • 1Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study (No. BZ0150), Beijing 100050, China.

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|July 30, 2013
PubMed

Insights

Death-effector domain-containing protein (DEDD) inhibits Smad3 activity and regulates apoptosis. The study found DEDD

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Death-effector domain-containing protein (DEDD) is involved in apoptosis regulation.
  • DEDD is known to inhibit Smad3-mediated transcriptional activity.
  • The precise role of DEDD's death-effector domain in Smad3 regulation and apoptosis requires further investigation.

Purpose of the Study:

  • To investigate how the death-effector domain of DEDD regulates Smad3 activity and apoptosis.
  • To elucidate the mechanisms by which DEDD influences Smad3 subcellular distribution, phosphorylation, and Smad4 interaction.
  • To determine the impact of DEDD and its mutants on cell apoptosis and proliferation.

Main Methods:

  • Immunoblotting, immunofluorescence, and immunoprecipitation were employed to assess DEDD's effects on Smad3.
  • Flow cytometry and MTT assays were utilized to evaluate DEDD's influence on cell apoptosis and proliferation.
  • Full-length DEDD and its truncated mutants (N-DEDD, C-DEDD) were used in the experiments.

Main Results:

  • DEDD and N-DEDD were found to inhibit TGF-beta1-induced Smad3 nuclear translocation.
  • The formation of the Smad3-Smad4 complex was inhibited by DEDD and N-DEDD.
  • DEDD and its mutants (N-DEDD, C-DEDD) induced cell apoptosis and inhibited cell proliferation.

Conclusions:

  • DEDD inhibits Smad3 activity via its death-effector domain.
  • Both truncated mutants of DEDD play a role in regulating apoptosis and cell proliferation.
  • DEDD is a key regulator of Smad3 signaling and cellular processes like apoptosis and proliferation.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...